SCHEMBL6654876

SCHEMBL6654876

CCCCCCN1CCC(C)(c2cccc(NC(C)=O)c2)C(C)C1

nearest known ligand 0.73

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 5/20 0.73
OPRK1 P41145 2/20 0.73
OPRD1 P41143 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6654874 1.00 OPRM1 (0.73) OPRM1OPRK1OPRD1
SCHEMBL6483819 0.91 OPRM1 (0.61) OPRM1OPRK1OPRD1
SCHEMBL6656655 0.90 OPRM1 (0.60) OPRM1OPRK1OPRD1
SCHEMBL6656656 0.90 OPRM1 (0.60) OPRM1OPRK1OPRD1
SCHEMBL6482564 0.90 OPRM1 (0.60) OPRM1OPRK1OPRD1
SCHEMBL6654366 0.89 OPRM1 (0.58) OPRM1OPRK1OPRD1
SCHEMBL6654368 0.89 OPRM1 (0.58) OPRM1OPRK1OPRD1
SCHEMBL6493074 0.87 OPRM1 (0.62) OPRM1OPRK1OPRD1
SCHEMBL6653770 0.87 OPRM1 (0.54) OPRM1OPRK1OPRD1
SCHEMBL6528597 0.87 OPRM1 (0.54) OPRM1OPRK1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1077940-B1 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES PFIZER (US) 2004-07-14 EP disclosed
US-6610711-B2 4-phenylpiperidines for the treatment of pruritic dermatoses PFIZER INC. 2003-08-26 US disclosed
US-20030078282-A1 Novel 4-phenylpiperidines for the treatment of pruritic dermatoses PFIZER INC. 2003-04-24 US disclosed
US-6441000-B1 DISEASES MEDIATED BY OPIATE RECEPTORS PFIZER INC 2002-08-27 US disclosed
EP-1055668-A1 New 4-arylpiperidine derivatives for the treatment of pruritus PFIZER INC. (US) 2000-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078282-A1 Novel 4-phenylpiperidines for the treatment of pruritic dermatoses HRH2, HRH4, HRH1 OPRM1 409/4885OPRK1 144/4885OPRD1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.